🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Published 22/08/2018, 22:44
© Reuters. FILE PHOTO: The Pfizer logo is seen at their world headquarters in New York
PFE
-
4503
-

(Reuters) - Drugmakers Pfizer Inc (N:PFE) and Astellas Pharma Inc (T:4503) said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

The companies now expect the ARCHES trial to end late this year, ahead of the previously anticipated completion date of April 2020, and the EMBARK trial to complete by mid-2020, earlier than the prior goal of March 2021.

Both trials are testing Xtandi in men with hormone-sensitive prostate cancer.

Xtandi is already approved in the United States to treat castration-resistant prostate cancer and brought Pfizer revenue of $171 million in the latest reported quarter.

Prostate cancer is the second most common cancer in men worldwide and over 164,000 men in the United States are estimated to be newly diagnosed with the disease this year, according to the American Cancer Society.

© Reuters. FILE PHOTO: The Pfizer logo is seen at their world headquarters in New York

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.